Profound Medical (PROF)
(Delayed Data from NSDQ)
$9.87 USD
-0.73 (-6.89%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $9.84 -0.03 (-0.30%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PROF 9.87 -0.73(-6.89%)
Will PROF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROF
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
Other News for PROF
Profound Medical (PRN) Receives a Buy from Lake Street
Profound Medical initiated with bullish view at Lake Street, here's why
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 ? Conference Call to Follow
Profound Medical Unveils Q2 2024 Financials
Profound Medical upgraded at Stifel on Medicare policy update